Pub Date : 2025-01-14eCollection Date: 2025-04-01DOI: 10.1515/mr-2024-0101
Jie Dong, Zeye Liu, Jing Dong, Fang Fang, Fengwen Zhang, Xiangbin Pan
The advancement of catheter-based interventional techniques represents a significant evolution in cardiovascular medicine. However, traditional methods that rely on fluoroscopic guidance present considerable limitations including radiation exposure and contrast agent-related risks and the heavy load-caused lead suits. In response, zero or low X-ray emerge, including percutaneous and non-fluoroscopical (PAN) procedure coming as a transformative solution, particularly in treating congenital heart disease, valvular disease, and arrhythmias. These methods minimize the risk of iatrogenic injuries associated with radiative procedures. Innovative PAN procedures and methodologies have been developed to enhance imaging, transcatheter interventions, safety, and accuracy, overcoming previous limitations. By eliminating radiation and expanding accessibility, PAN procedures offer a safe, effective, and economically viable alternative to traditional methods, ushering in a new era of minimally invasive cardiovascular treatment.
{"title":"Embracing a new era of echocardiography-guided percutaneous and non-fluoroscopical procedure for structure heart disease.","authors":"Jie Dong, Zeye Liu, Jing Dong, Fang Fang, Fengwen Zhang, Xiangbin Pan","doi":"10.1515/mr-2024-0101","DOIUrl":"https://doi.org/10.1515/mr-2024-0101","url":null,"abstract":"<p><p>The advancement of catheter-based interventional techniques represents a significant evolution in cardiovascular medicine. However, traditional methods that rely on fluoroscopic guidance present considerable limitations including radiation exposure and contrast agent-related risks and the heavy load-caused lead suits. In response, zero or low X-ray emerge, including percutaneous and non-fluoroscopical (PAN) procedure coming as a transformative solution, particularly in treating congenital heart disease, valvular disease, and arrhythmias. These methods minimize the risk of iatrogenic injuries associated with radiative procedures. Innovative PAN procedures and methodologies have been developed to enhance imaging, transcatheter interventions, safety, and accuracy, overcoming previous limitations. By eliminating radiation and expanding accessibility, PAN procedures offer a safe, effective, and economically viable alternative to traditional methods, ushering in a new era of minimally invasive cardiovascular treatment.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 2","pages":"174-176"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11987503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: With the popularity of yoga increasing as a means to improve overall well-being, this umbrella review aimed to evaluate the potential effects of yoga on chronic disease outcomes by synthesizing previously published systematic reviews, including meta-analyses, of randomized controlled trials in adult populations.
Content: PubMed, Scopus, Cochrane, Web of Science, and CINAHL for systematic reviews published up to 31st March 2023. Systematic reviews examining the effectiveness of yoga interventions compared with controllable groups on chronic disease outcomes were searched from adults aged above 18 years old. Fifty-one systematic reviews, of which 34 were with meta-analyses, were eligible. The included reviews yielded 579 individual studies with 28403 reported participants. Most studies (n=45, 86.5 %) were conducted with general adult participants, other six studies were with women diagnosed with breast cancer. Yoga interventions had strong effects on depression, blood pressure, blood glucose, and fatigue management, while weak evidence was found for pain management and arthritis.
Summary: Yoga intervention may have an effect on improvements on depression, hypertension, type 2 diabetes, and fatigue management but not beneficial for physically disordered chronic diseases.
Outlook: Future studies with larger sample sizes and longer durations are necessary to validate the effect of yoga on chornic diseases. Further exploration on yoga implementation are expected.
Primary funding source: JIF201036Y and JIF201018Y (PROSPERO: CRD42023417841).
随着瑜伽作为一种改善整体健康的手段越来越受欢迎,本综述旨在通过综合先前发表的成人随机对照试验的系统综述,包括荟萃分析,来评估瑜伽对慢性疾病结局的潜在影响。内容:PubMed, Scopus, Cochrane, Web of Science和CINAHL,截至2023年3月31日发表的系统综述。从18岁以上的成年人中检索了检查瑜伽干预与可控组对慢性疾病结局的有效性的系统综述。51项系统评价,其中34项采用荟萃分析,符合条件。纳入的综述产生了579项单独研究,报告了28403名参与者。大多数研究(n=45, 86.5 %)是在普通成人参与者中进行的,另外6项研究是在诊断为乳腺癌的女性中进行的。瑜伽干预对抑郁、血压、血糖和疲劳管理有很强的影响,而对疼痛管理和关节炎的证据却很弱。总结:瑜伽干预可能对改善抑郁、高血压、2型糖尿病和疲劳管理有影响,但对身体紊乱的慢性疾病没有好处。展望:未来的研究需要更大的样本量和更长的持续时间来验证瑜伽对慢性疾病的影响。期望对瑜伽的实施进行进一步的探索。主要资金来源:JIF201036Y和JIF201018Y (PROSPERO: CRD42023417841)。
{"title":"Yoga and chronic diseases: an umbrella review of systematic reviews and meta-analyses.","authors":"Feifei Wang, Wenchang Yang, Chen Wang, Kaiyue Wang, Zhongyi Yu, Dandan Ke, Liang Sun, Xiang Gao","doi":"10.1515/mr-2024-0078","DOIUrl":"10.1515/mr-2024-0078","url":null,"abstract":"<p><strong>Introduction: </strong>With the popularity of yoga increasing as a means to improve overall well-being, this umbrella review aimed to evaluate the potential effects of yoga on chronic disease outcomes by synthesizing previously published systematic reviews, including meta-analyses, of randomized controlled trials in adult populations.</p><p><strong>Content: </strong>PubMed, Scopus, Cochrane, Web of Science, and CINAHL for systematic reviews published up to 31st March 2023. Systematic reviews examining the effectiveness of yoga interventions compared with controllable groups on chronic disease outcomes were searched from adults aged above 18 years old. Fifty-one systematic reviews, of which 34 were with meta-analyses, were eligible. The included reviews yielded 579 individual studies with 28403 reported participants. Most studies (n=45, 86.5 %) were conducted with general adult participants, other six studies were with women diagnosed with breast cancer. Yoga interventions had strong effects on depression, blood pressure, blood glucose, and fatigue management, while weak evidence was found for pain management and arthritis.</p><p><strong>Summary: </strong>Yoga intervention may have an effect on improvements on depression, hypertension, type 2 diabetes, and fatigue management but not beneficial for physically disordered chronic diseases.</p><p><strong>Outlook: </strong>Future studies with larger sample sizes and longer durations are necessary to validate the effect of yoga on chornic diseases. Further exploration on yoga implementation are expected.</p><p><strong>Primary funding source: </strong>JIF201036Y and JIF201018Y (PROSPERO: CRD42023417841).</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 3","pages":"244-255"},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-06eCollection Date: 2025-06-01DOI: 10.1515/mr-2024-0065
Junxuan Lü, Cheng Jiang, Hongbo Hu
Selenium (Se) is an essential trace mineral crucial for human health. Nearly a dozen human clinical trials with seleno-methionine (SeMet) and selenized-yeast (contains mostly SeMet) for the prevention of non-cutaneous solid organ cancers in North America and European countries conclusively refuted their utility. We have articulated two lessons from these trials: (1) the anti-oxidant hypothesis was tested in inappropriate Se-adequate populations, and (2) the selection of these Se forms was not supported by cell culture and animal efficacy data. Nevertheless, preclinical studies of proximal methylselenol precursors ("methyl Se") have shown many desirable attributes, involving crucial molecules and pathways in cancer epithelial cells, vascular endothelial, immune and inflammatory cells in the tumor microenvironment, for potential use as chemopreventive and therapy agents. Methylseleninic acid and Se-methylselenocysteine are prototypical methyl-Se, yet not equal in their targets. Selenate, selenite and selenious acid had been recently studied in human clinical trials, providing novel safety data, but, missing critical genotoxicity assessments. Given the popularity of Se-enriched foods in China and a continued presence of nutritional Se deficiency in many localities, we discuss recommendations for clinical studies of Se forms for cancer therapy or chemoprevention in China and other countries with similar Se nutrition predicament.
{"title":"Selenium compounds for cancer prevention and therapy - human clinical trial considerations.","authors":"Junxuan Lü, Cheng Jiang, Hongbo Hu","doi":"10.1515/mr-2024-0065","DOIUrl":"10.1515/mr-2024-0065","url":null,"abstract":"<p><p>Selenium (Se) is an essential trace mineral crucial for human health. Nearly a dozen human clinical trials with seleno-methionine (SeMet) and selenized-yeast (contains mostly SeMet) for the prevention of non-cutaneous solid organ cancers in North America and European countries conclusively refuted their utility. We have articulated two lessons from these trials: (1) the anti-oxidant hypothesis was tested in inappropriate Se-adequate populations, and (2) the selection of these Se forms was not supported by cell culture and animal efficacy data. Nevertheless, preclinical studies of proximal methylselenol precursors (\"methyl Se\") have shown many desirable attributes, involving crucial molecules and pathways in cancer epithelial cells, vascular endothelial, immune and inflammatory cells in the tumor microenvironment, for potential use as chemopreventive and therapy agents. Methylseleninic acid and Se-methylselenocysteine are prototypical methyl-Se, yet not equal in their targets. Selenate, selenite and selenious acid had been recently studied in human clinical trials, providing novel safety data, but, missing critical genotoxicity assessments. Given the popularity of Se-enriched foods in China and a continued presence of nutritional Se deficiency in many localities, we discuss recommendations for clinical studies of Se forms for cancer therapy or chemoprevention in China and other countries with similar Se nutrition predicament.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 3","pages":"203-230"},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-24eCollection Date: 2025-04-01DOI: 10.1515/mr-2024-0077
Wenhua Huang, Seogsong Jeong, Won Kim, Lei Chen
Organoid technology has significantly transformed biomedical research by providing exceptional prospects for modeling human tissues and disorders in a laboratory setting. It has significant potential for understanding the intricate relationship between genetic mutations, cellular phenotypes, and disease pathology, especially in the field of genetic diseases. The intersection of organoid technology and genetic research offers great promise for comprehending the pathophysiology of genetic diseases and creating innovative treatment approaches customized for specific patients. This review aimed to present a thorough analysis of the current advancements in organoid technology and its biomedical applications for genetic diseases. We examined techniques for modeling genetic disorders using organoid platforms, analyze the approaches for incorporating genetic disease organoids into clinical practice, and showcase current breakthroughs in preclinical application, individualized healthcare, and transplantation. Through the integration of knowledge from several disciplines, such as genetics, regenerative medicine, and biological engineering, our aim is to enhance our comprehension of the complex connection between genetic variations and organoid models in relation to human health and disease.
{"title":"Biomedical applications of organoids in genetic diseases.","authors":"Wenhua Huang, Seogsong Jeong, Won Kim, Lei Chen","doi":"10.1515/mr-2024-0077","DOIUrl":"https://doi.org/10.1515/mr-2024-0077","url":null,"abstract":"<p><p>Organoid technology has significantly transformed biomedical research by providing exceptional prospects for modeling human tissues and disorders in a laboratory setting. It has significant potential for understanding the intricate relationship between genetic mutations, cellular phenotypes, and disease pathology, especially in the field of genetic diseases. The intersection of organoid technology and genetic research offers great promise for comprehending the pathophysiology of genetic diseases and creating innovative treatment approaches customized for specific patients. This review aimed to present a thorough analysis of the current advancements in organoid technology and its biomedical applications for genetic diseases. We examined techniques for modeling genetic disorders using organoid platforms, analyze the approaches for incorporating genetic disease organoids into clinical practice, and showcase current breakthroughs in preclinical application, individualized healthcare, and transplantation. Through the integration of knowledge from several disciplines, such as genetics, regenerative medicine, and biological engineering, our aim is to enhance our comprehension of the complex connection between genetic variations and organoid models in relation to human health and disease.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 2","pages":"152-163"},"PeriodicalIF":0.0,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11987506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alzheimer's disease (AD) is a chronic neurodegenerative disorder for which there are currently no effective treatment options. Increasing evidence suggests that AD is a systemic disease closely associated with the immune system, not merely a central nervous system (CNS) disorder. Immune cells play crucial roles in the onset and progression of AD. Microglia and astrocytes are the primary inflammatory cells in the brain that can sensitively detect changes in the internal environment and transform into different phenotypes to exert differing effects at various stages of AD. Peripheral immune cells, such as T cells, B cells, monocytes/macrophages, and neutrophils can also be recruited to the CNS to mediate the inflammatory response in AD. As such, investigating the role of immune cells in AD is particularly important for elucidating its specific pathogenesis. This review primarily discusses the roles of central innate immune cells, peripheral immune cells, and the interactions between central and peripheral immune cells in the development of neuroinflammation in AD. Furthermore, we listed clinical trials targeting AD-associated neuroinflammation, which may represent a promising direction for developing effective treatments for AD in the future.
{"title":"Immune cells in Alzheimer's disease: insights into pathogenesis and potential therapeutic targets.","authors":"Xiaofeng Fu, Huimin Cai, Shuiyue Quan, Ziye Ren, Yinghao Xu, Longfei Jia","doi":"10.1515/mr-2024-0064","DOIUrl":"10.1515/mr-2024-0064","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a chronic neurodegenerative disorder for which there are currently no effective treatment options. Increasing evidence suggests that AD is a systemic disease closely associated with the immune system, not merely a central nervous system (CNS) disorder. Immune cells play crucial roles in the onset and progression of AD. Microglia and astrocytes are the primary inflammatory cells in the brain that can sensitively detect changes in the internal environment and transform into different phenotypes to exert differing effects at various stages of AD. Peripheral immune cells, such as T cells, B cells, monocytes/macrophages, and neutrophils can also be recruited to the CNS to mediate the inflammatory response in AD. As such, investigating the role of immune cells in AD is particularly important for elucidating its specific pathogenesis. This review primarily discusses the roles of central innate immune cells, peripheral immune cells, and the interactions between central and peripheral immune cells in the development of neuroinflammation in AD. Furthermore, we listed clinical trials targeting AD-associated neuroinflammation, which may represent a promising direction for developing effective treatments for AD in the future.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 3","pages":"179-202"},"PeriodicalIF":0.0,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lactate is the end product of glycolysis, and extensive research has shown that lactate participates in various pathophysiological processes. Along with associated hydrogen ions, lactate typically functions as an immunosuppressive negative factor and plays a crucial role in tumor metabolic reprogramming. The recently discovered lactylation is a novel epigenetic modification that, similar to other epigenetic modifications, modifies histones to alter chromatin spatial configuration, thereby affecting DNA accessibility and regulating gene expression. More importantly, the degree of lactylation is closely related to local lactate concentrations, establishing a link between epigenetics and metabolic reprogramming. During cellular metabolism, lactate accumulation promotes histone lysine lactylation in cancer cells and immune cells such as macrophages and T cells, playing an essential role in tumor immune evasion and resistance to immunotherapy. This paper details the role of lactylation modifications in cancer immune evasion and resistance to immunotherapy, providing novel therapeutic directions and targets for cancer treatment.
{"title":"Histone lactylation as a driver of metabolic reprogramming and immune evasion.","authors":"Qiaoting Cai, Wei Deng, Yutian Zou, Zhe-Sheng Chen, Hailin Tang","doi":"10.1515/mr-2024-0091","DOIUrl":"10.1515/mr-2024-0091","url":null,"abstract":"<p><p>Lactate is the end product of glycolysis, and extensive research has shown that lactate participates in various pathophysiological processes. Along with associated hydrogen ions, lactate typically functions as an immunosuppressive negative factor and plays a crucial role in tumor metabolic reprogramming. The recently discovered lactylation is a novel epigenetic modification that, similar to other epigenetic modifications, modifies histones to alter chromatin spatial configuration, thereby affecting DNA accessibility and regulating gene expression. More importantly, the degree of lactylation is closely related to local lactate concentrations, establishing a link between epigenetics and metabolic reprogramming. During cellular metabolism, lactate accumulation promotes histone lysine lactylation in cancer cells and immune cells such as macrophages and T cells, playing an essential role in tumor immune evasion and resistance to immunotherapy. This paper details the role of lactylation modifications in cancer immune evasion and resistance to immunotherapy, providing novel therapeutic directions and targets for cancer treatment.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 3","pages":"256-259"},"PeriodicalIF":0.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-29eCollection Date: 2025-04-01DOI: 10.1515/mr-2024-0060
Aminath Fazna, Randi Jenssen Hagerman
Fragile X syndrome (FXS) is a genetic disorder caused by a mutation in the FMR1 gene on the X chromosome, leading to a range of developmental and intellectual disabilities. FXS is characterized by intellectual disability, behavior challenges, and distinct physical features such as an elongated face, large ears, and hyperflexible joints; FXS remains the most common inherited cause of intellectual disability. Behavioral manifestations often include attention deficits, hyperactivity, anxiety, and features of autism spectrum disorder. The prevalence of FXS in the South Asian population is not well-documented, but existing studies suggest it may be comparable to global prevalence rates, which are approximately 1 in 4,000 males and 1 in 8,000 females. Accurate diagnosis of FXS in South Asians is crucial due to the implications for early intervention and treatment, which can significantly improve the quality of life and developmental outcomes for affected individuals. Early diagnosis also facilitates genetic counselling and family planning, helping to reduce the risk of recurrence in families. Increased awareness and screening in South Asian communities are essential to address the diagnostic gap and ensure timely support for individuals with FXS or disorders associated with the premutation of FMR1.
{"title":"Prevalence of fragile X syndrome in South Asia, and importance of diagnosis.","authors":"Aminath Fazna, Randi Jenssen Hagerman","doi":"10.1515/mr-2024-0060","DOIUrl":"https://doi.org/10.1515/mr-2024-0060","url":null,"abstract":"<p><p>Fragile X syndrome (FXS) is a genetic disorder caused by a mutation in the <i>FMR1</i> gene on the X chromosome, leading to a range of developmental and intellectual disabilities. FXS is characterized by intellectual disability, behavior challenges, and distinct physical features such as an elongated face, large ears, and hyperflexible joints; FXS remains the most common inherited cause of intellectual disability. Behavioral manifestations often include attention deficits, hyperactivity, anxiety, and features of autism spectrum disorder. The prevalence of FXS in the South Asian population is not well-documented, but existing studies suggest it may be comparable to global prevalence rates, which are approximately 1 in 4,000 males and 1 in 8,000 females. Accurate diagnosis of FXS in South Asians is crucial due to the implications for early intervention and treatment, which can significantly improve the quality of life and developmental outcomes for affected individuals. Early diagnosis also facilitates genetic counselling and family planning, helping to reduce the risk of recurrence in families. Increased awareness and screening in South Asian communities are essential to address the diagnostic gap and ensure timely support for individuals with FXS or disorders associated with the premutation of <i>FMR1.</i></p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"5 2","pages":"164-173"},"PeriodicalIF":0.0,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11987505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alzheimer's disease (AD) is a gradually progressive neurodegenerative disease with tremendous social and economic burden. Therefore, early and accurate diagnosis is imperative for effective treatment or prevention of the disease. Cerebrospinal fluid and blood biomarkers emerge as favorable diagnostic tools due to their relative accessibility and potential for widespread clinical use. This review focuses on the AT(N) biomarker system, which includes biomarkers reflecting AD core pathologies, amyloid deposition, and pathological tau, as well as neurodegeneration. Novel biomarkers associated with inflammation/immunity, synaptic dysfunction, vascular pathology, and α-synucleinopathy, which might contribute to either the pathogenesis or the clinical progression of AD, have also been discussed. Other emerging candidates including non-coding RNAs, metabolites, and extracellular vesicle-based markers have also enriched the biofluid biomarker landscape for AD. Moreover, the review discusses the current challenges of biofluid biomarkers in AD diagnosis and offers insights into the prospective future development.
{"title":"Biofluid biomarkers for Alzheimer's disease: past, present, and future.","authors":"Chengyu An, Huimin Cai, Ziye Ren, Xiaofeng Fu, Shuiyue Quan, Longfei Jia","doi":"10.1515/mr-2023-0071","DOIUrl":"10.1515/mr-2023-0071","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a gradually progressive neurodegenerative disease with tremendous social and economic burden. Therefore, early and accurate diagnosis is imperative for effective treatment or prevention of the disease. Cerebrospinal fluid and blood biomarkers emerge as favorable diagnostic tools due to their relative accessibility and potential for widespread clinical use. This review focuses on the AT(N) biomarker system, which includes biomarkers reflecting AD core pathologies, amyloid deposition, and pathological tau, as well as neurodegeneration. Novel biomarkers associated with inflammation/immunity, synaptic dysfunction, vascular pathology, and α-synucleinopathy, which might contribute to either the pathogenesis or the clinical progression of AD, have also been discussed. Other emerging candidates including non-coding RNAs, metabolites, and extracellular vesicle-based markers have also enriched the biofluid biomarker landscape for AD. Moreover, the review discusses the current challenges of biofluid biomarkers in AD diagnosis and offers insights into the prospective future development.</p>","PeriodicalId":74151,"journal":{"name":"Medical review (Berlin, Germany)","volume":"4 6","pages":"467-491"},"PeriodicalIF":0.0,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}